CRNX (Crinetics Pharmaceuticals) Interest Coverage: N/A (As of Mar. 2026)


CRNX Crinetics Pharmaceuticals Inc CRNX
41 GF Score
Price $43.81
GF Value $717.51
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Crinetics Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was $-140.38 Mil. Crinetics Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Crinetics Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Crinetics Pharmaceuticals's Interest Coverage or its related term are showing as below:


CRNX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 110.86
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Crinetics Pharmaceuticals  (NAS:CRNX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Crinetics Pharmaceuticals Interest Coverage Related Terms


Crinetics Pharmaceuticals Interest Coverage Historical Data

* Premium members only.

The historical data trend for Crinetics Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Crinetics Pharmaceuticals Interest Coverage Chart

Crinetics Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Crinetics Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

CRNX vs CPRX, NAMS, RCUS: Interest Coverage Comparison

For the Biotechnology subindustry, Crinetics Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crinetics Pharmaceuticals Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Crinetics Pharmaceuticals's Interest Coverage falls into.


CRNX
41GF Score
Crinetics Pharmaceuticals Inc CRNX
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crinetics Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Crinetics Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Crinetics Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-516.77 Mil. And its Long-Term Debt & Capital Lease Obligation was $42.05 Mil.

GuruFocus does not calculate Crinetics Pharmaceuticals's interest coverage with the available data.

Crinetics Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Crinetics Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-140.38 Mil. And its Long-Term Debt & Capital Lease Obligation was $41.32 Mil.

GuruFocus does not calculate Crinetics Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Is Crinetics Pharmaceuticals (CRNX) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of $43.81 is trading 93.9% below its estimated GF Value™ of $717.51. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CRNX:

  • Interest Coverage: N/A
  • GF Value™: $717.51 vs. price of $43.81 (93.9% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the CRNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Crinetics Pharmaceuticals Business Description

Other Exchanges 6Z4:Germany
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
41GF Score

Get the complete analysis for CRNX

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.81
Price
$717.51
GF Value